Pacira BioSciences, Inc.

NasdaqGS:PCRX Stock Report

Market Cap: US$1.4b

Pacira BioSciences Dividend

Dividend criteria checks 0/6

Pacira BioSciences does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.3%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per shareUS$0.90
Dividend yield forecast in 3Yn/a

Recent dividend updates

No updates

Recent updates

Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?

Feb 05
Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement

Jan 05
Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Nov 03
We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?

Jul 28
Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price

Jul 07
Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price

Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

Apr 18
Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Dec 28
We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Assessing Pacira BioSciences' Growth Prospects

Oct 20

Pacira BioSciences guides Q3 revenue below consensus

Oct 13

Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures

Sep 27

EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids

Sep 20

Pacira BioSciences records 17.7% sequential growth in August revenue

Sep 13

Pacira BioSciences provides update on July product sales

Aug 10

Pacira BioSciences Q2 2022 Earnings Preview

Aug 02

Pacira BioSciences sees Q2 revenue below consensus

Jul 14

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Reasonably Well

Apr 04
These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Reasonably Well

Pacira BioSciences: Higher Prices On The Horizon

Dec 20

Investors Appear Satisfied With Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Prospects

Nov 29
Investors Appear Satisfied With Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Prospects

Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Rather Sparingly

Oct 15
Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Rather Sparingly

Pacira BioSciences: Attractive Capital Gain Odds Next 3 Months

Sep 17

Pacira Biosciences' EXPAREL average daily sales more than doubles in May

Jun 08

Pacira Bio's Exparel fails to reach primary endpoint in late-stage STRIDE study

May 26

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if PCRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PCRX's dividend payments have been increasing.


Dividend Yield vs Market

Pacira BioSciences Dividend Yield vs Market
How does PCRX dividend yield compare to the market?
SegmentDividend Yield
Company (PCRX)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.8%
Industry Average (Pharmaceuticals)2.3%
Analyst forecast in 3 Years (PCRX)n/a

Notable Dividend: Unable to evaluate PCRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PCRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate PCRX's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PCRX has not reported any payouts.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.